This study provides a novel radionuclide strategy for the precision diagnosis and treatment of multiple myeloma, suggesting that matching long-half-life radionuclides to antibody pharmacokinetics is key to enhancing efficacy in the development of BCMA-targeted therapies.
Literature Overview
The article "Radiocopper in BCMA-targeted immunotheranostics of myeloma," published in Theranostics, systematically explores the potential of copper-64 (for PET imaging) and copper-67 (for SPECT imaging and therapy) as a "true" matched radionuclide pair in the theranostic application of monoclonal antibody-mediated multiple myeloma targeting the B-cell maturation antigen (BCMA).Background Knowledge
Multiple myeloma is a malignant proliferative disease of plasma cells. Although BCMA has become a critical target for immunotherapy, patients still face challenges of relapse and drug resistance. Current development of BCMA-targeted radiopharmaceuticals faces bottlenecks: traditional radionuclides like Gallium-68 have half-lives that are too short to match the slow pharmacokinetics of antibodies, while therapeutic radionuclides like Lutetium-177 lack ideal diagnostic partners of the same element, leading to imprecise dosimetry planning. This study leverages the physical properties of copper-64 (half-life 12.7 hours) and copper-67 (half-life 61.8 hours), combined with the highly stable bispidine chelator, to construct an immunotheranostic probe capable of precise tumor visualization and efficient radiotherapy. The aim is to address difficulties in dose monitoring and lagging efficacy assessment in the treatment of multiple myeloma.
Research Methods and Core Experiments
The authors selected two commercial anti-BCMA monoclonal antibodies, MAB193 and Vicky-1, and conjugated them using the bifunctional bispidine chelator N2py4-Bn-NCS. The binding affinity of the conjugates was verified via surface plasmon resonance (SPR) and flow cytometry. Subcutaneous xenograft mouse models of multiple myeloma (U266 and L363) expressing different levels of BCMA were established, along with a BCMA-negative A375 melanoma model as a control. To eliminate interference from circulating soluble BCMA (sBCMA), mice were pre-treated with a gamma-secretase inhibitor (GSI). Subsequently, small-animal PET imaging was used to evaluate the in vivo distribution, pharmacokinetics, and tumor uptake of copper-64-labeled antibodies. Furthermore, a pilot study on radioimmunotherapy using copper-67-labeled antibodies was conducted in the U266 model, combined with quantitative SPECT imaging for dosimetry estimation.Key Conclusions and Perspectives
Research Significance and Prospects
This study not only validates the feasibility of the copper radionuclide pair in the theranostics of multiple myeloma but also emphasizes the importance of selecting radionuclides based on antibody pharmacokinetic characteristics. For drug development, this suggests that future BCMA-targeted therapeutics should prioritize carrier designs compatible with long-half-life radionuclides. In terms of clinical monitoring, using copper-64 PET for precise dose planning combined with copper-67 SPECT for real-time efficacy assessment holds promise for resolving current issues of under-dosing or overtreatment in immunotherapy. Additionally, the xenograft models and dosimetry calculation methods established in this study provide a standardized reference for other disease modeling and radiopharmaceutical evaluations.
Conclusion
Through rigorous preclinical experiments, this study successfully constructed a BCMA-targeted immunotheranostic platform based on the copper-64/67 matched pair. The results indicate that [64Cu]Cu-N2py4-MAB193 can not only precisely identify multiple myeloma lesions but also enable efficient therapeutic radiation delivery via [67Cu]Cu-N2py4-MAB193. This discovery marks a critical step in radionuclide therapy, moving from empirical dosing to precision dosimetry planning. For the care system of multiple myeloma, this strategy is expected to optimize treatment regimens through non-invasive imaging, improving patient survival rates and reducing side effects. In the future, with the maturation of copper-67 production technology and deeper clinical translation research, this "theranostic" model will become a cornerstone of precision medicine for hematological malignancies, driving BCMA-targeted therapies into new clinical phases.
